Several agents that were meant to be used in combination with anti-VEGFs have not met expectations. Though new approaches might still be worth pursuing, proper use of currently available treatments, following validated protocols, should have priority, according to Jordi Monés, MD, PhD.
Perspective: Jordi Monés, MD, PhD
Other Perspective
Treat and Extend – Practical guide
Treat and Extend (T&E) has gained wide popularity as a proactive, pragmatic, individualized regi
Biosimilars, a new frontier?
Biosimilars entering the scene of intravitreal injections
Anti-VEGF therapies for AMD: where are we now?
Where are we now with the spread of these therapies for AMD to prevent blindness?
Defining Nonadherence and Nonpersistence to Anti-VEGF Therapies in nAMD
The nAMD Barometer Leadership Coalition published a definition for nonadherence and nonpersistence
Related Articles
